A Malaria Drug Compound (Also Called ‘DHA’) Studied for Liver Fibrosis — Not Fish Oil DHA
This laboratory study investigated a compound called dihydroartemisinin — which is also abbreviated “DHA” but is completely different from the omega-3 fatty acid docosahexaenoic acid (also called DHA) found in fish oil. Dihydroartemisinin is derived from the artemisinin family of compounds, historically used for malaria treatment.
Researchers explored how this compound affects copper and iron handling inside liver stellate cells, which play a key role in liver fibrosis (scarring). They found that the compound triggered a chain of cellular events involving copper transport proteins, mitochondrial copper uptake, and two forms of regulated cell death called cuproptosis (copper-triggered) and ferroptosis (iron-triggered).
The team also engineered specialized nanoparticle delivery systems coated with cell membrane components to specifically target liver stellate cells in rodent models, aiming to concentrate the compound’s effects on fibrosis-related cells.
What this means for you
Because this study used dihydroartemisinin — a malaria-related compound unrelated to omega-3 fish oil DHA — it does not provide information about omega-3 fatty acids, fish oil, or EPA/DHA supplementation. It’s included here only for educational transparency about the shared abbreviation, and the findings relate to laboratory and rodent research on liver cell biology, not human supplementation outcomes.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
International journal of biological sciences · 2026-01-01 · DOI: 10.7150/ijbs.134520
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.